| アブストラクト | BACKGROUND: Japanese guidelines recommend triple therapy with vonoprazan or a proton pump inhibitor (PPI) in combination with antibiotics to treat Helicobacter pylori (H. pylori) infection. While studies have shown improved eradication rates and reduced costs with vonoprazan versus PPIs, there is little data describing healthcare resource use (HCRU) and treatment patterns. OBJECTIVES: To compare patients treated with a vonoprazan-based or PPI-based regimen for H. pylori infection in Japan in terms of their characteristics, HCRU, healthcare costs, clinical outcomes, and treatment patterns. DESIGN: Retrospective matched cohort. METHODS: We used data from the Japan Medical Data Center claims database (July 2014-January 2020) to identify adult patients with H. pylori infection and a first observed use of vonoprazan or a PPI in 2015 or later (index date). Patients prescribed a vonoprazan-based or a PPI-based regimen were matched 1:1 using propensity score matching. HCRU, healthcare costs, diagnostic tests, a proxy for H. pylori eradication (i.e. no triple therapy with amoxicillin in combination with metronidazole or clarithromycin >30 days after the index date), and second-line treatment were described during the 12-month follow-up period. RESULTS: Among 25,389 matched pairs, vonoprazan-treated patients had fewer all-cause and H. pylori-related inpatient stays and outpatient visits than PPI-treated patients, resulting in lower all-cause healthcare costs [185,378 Japanese yen (JPY) versus 230,876 JPY, p < 0.001]. Over 80% of patients received a post-treatment test for H. pylori. Fewer vonoprazan-treated than PPI-treated patients subsequently received an additional triple regimen for H. pylori infection (7.1% versus 20.0%, p < 0.001) or a prescription for vonoprazan or a PPI as monotherapy (12.4% versus 26.4%, p < 0.001) between 31 days and 12 months after the index date. CONCLUSION: Patients with H. pylori infection who were treated with vonoprazan-based therapy had lower rates of subsequent H. pylori treatment, lower overall and H. pylori-related HCRU, and lower healthcare costs than patients treated with PPI-based therapy. |
|---|
| ジャーナル名 | Therapeutic advances in gastroenterology |
|---|
| Pubmed追加日 | 2023/5/8 |
|---|
| 投稿者 | Howden, Colin W; Cook, Erin E; Swallow, Elyse; Yang, Karen; Guo, Helen; Pelletier, Corey; Jacob, Rinu; Sugano, Kentaro |
|---|
| 組織名 | University of Tennessee College of Medicine, Memphis, TN 38163, USA.;Analysis Group, Inc., Boston, MA, USA.;Analysis Group, Inc., New York, NY, USA.;Analysis Group, Inc., Los Angeles, CA, USA.;Phathom Pharmaceuticals, Florham Park, NJ, USA.;Jichi Medical University, Shimotsuke, Tochigi, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37153499/ |
|---|
